WANY
PCRX icon

Wealthspire Advisors (New York)’s Pacira BioSciences PCRX Stock Holding History

Wealthspire Advisors (New York)’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-28
Closed -$722 – 2334
2025
Q3 		$722 Buy
+28
New +$688 ﹤0.01% 2786

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wealthspire Advisors (New York)'s PCRX Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Pacira BioSciences (PCRX) in Q4 2025, closing a stake of 28 shares — an estimated $722 sold.

Wealthspire Advisors (New York) first reported a position in PCRX in Q3 2025 and held it in 1 quarter. The position peaked at $722 in Q3 2025. 260 funds tracked by Wall St. Rank hold PCRX as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Pacira BioSciences position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 28 Pacira BioSciences shares in Q4 2025, an estimated $722.
  • Wealthspire Advisors (New York) first reported a position in Pacira BioSciences in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Pacira BioSciences position peaked at $722 in Q3 2025.
  • 260 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.